TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: An association with predicted neoantigen heterogeneity and postsurgical recurrence

Cancer Discovery

Volumn 7, Issue 10, 2017, Pages 1088-1097

  Reuben, Alexandre ^a   Gittelman, Rachel ^b   Gao, Jianjun ^a   Zhang, Jiexin ^a   Yusko, Erik C ^b   Wu, Chang Jiun ^a   Emerson, Ryan ^b   Zhang, Jianhua ^a   Tipton, Christopher ^b,d   Li, Jun ^a   Quek, Kelly ^a   Gopalakrishnan, Vancheswaran ^a   Chen, Runzhe ^a   Vence, Luis M ^a   Cascone, Tina ^a   Vignali, Marissa ^b   Fujimoto, Junya ^a   Rodriguez Canales, Jaime ^a   Parra, Edwin R ^a   Little, Latasha D ^a   Gumbs, Curtis ^a   Forget, Marie Andree ^a   Federico, Lorenzo ^a   Haymaker, Cara ^a   Behrens, Carmen ^a   Benzeno, Sharon ^b   Bernatchez, Chantale ^a   Sepesi, Boris ^a   Gibbons, Don L ^a   Wargo, Jennifer A ^a   William, William N ^a   Swisher, Stephen ^a   Heymach, John V ^a   Robins, Harlan ^b,c   Lee, J Jack ^a   Sharma, Padmanee ^a   Allison, James P ^a   Futreal, P Andrew ^a   Wistuba, Ignacio I ^a   Zhang, Jianjun ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ADAPTIVE BIOTECHNOLOGIES   (United States)

^c USA   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CISPLATIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEOANTIGEN; PEMETREXED; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN HETEROGENEITY; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CELL DENSITY; CELL HETEROGENEITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLONAL VARIATION; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MORISITA OVERLAP INDEX; MUTATION; NON SMALL CELL LUNG CANCER; POSTOPERATIVE CARE; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; T LYMPHOCYTE; TUMOR IMMUNOGENICITY; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; IMMUNOLOGY; LUNG TUMOR; PROCEDURES; TUMOR RECURRENCE; WHOLE EXOME SEQUENCING;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ANTIGEN, T-CELL; WHOLE EXOME SEQUENCING;

EID: 85030726300     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0256     Document Type: Article

References (34)

1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–65.
4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmall- cell lung cancer. N Engl J Med 2015;373:1627–39.
5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–32.
6. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.
7. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616–22.
8. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–26.
9. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–30.
10. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–33.
11. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–9.
12. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847–56.
13. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
14. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256–9.
15. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351:1463–9.
16. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.
17. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti- CTLA-4 treatment in cancer patients. Sci Transl Med 2014;6:238ra70.
18. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.
19. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, et al. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin Cancer Res 2016;22:6278–89.
20. Federico L, Haymaker C, Forget M-A, Vence L, Team I, Sharma P, et al. P1.05–028 phenotypic and functional profiling of tumor-infiltrating lymphocytes (TIL) in early stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2017;12:S630–S631.
21. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61.
22. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11:215–33.
23. Ng F, Kozarski R, Ganeshan B, Goh V. Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol 2013;82:342–8.
24. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935–45.
25. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Res 2008;36:W509–12.
26. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 2008;24:1397–8.
27. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007;2:e796.
28. Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 2015;33:1152–8.
29. Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics 2015;67:641–50.
30. Bai Y, Ni M, Cooper B, Wei Y, Fury W. Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads. BMC Genomics 2014;15:325.
31. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor betachain diversity in alphabeta T cells. Blood 2009;114:4099–107.
32. Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 2013;4:2680.
33. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods 2012;375:14–9.
34. Kirsch I, Vignali M, Robins H. T-cell receptor profiling in cancer. Mol Oncol 2015;9:2063–70.